ANTITUMOR ACTIVITY OF A NOVEL FGFR INHIBITOR IN INTRAHEPATIC CHOLANGIOCARCINOMA

被引：0

作者：

Raggi, Chiara ^{[1
]}

Fiaccadori, Karim ^{[2
]}

Pastore, Mirella ^{[1
]}

Correnti, Margherita ^{[2
]}

Piombanti, Benedetta ^{[1
]}

Forti, Elisa ^{[2
]}

Navari, Nadia ^{[1
]}

Abbadessa, Giovanni ^{[3
]}

Hall, Terence ^{[3
]}

Destro, Annarita ^{[2
]}

Di Tommaso, Luca ^{[4
]}

Roncalli, Massimo ^{[5
]}

Meng, Fanyin ^{[6
,7
]}

Glaser, Shannon S. ^{[8
]}

Rovida, Elisabetta ^{[1
]}

Peraldo-Neia, Caterina ^{[9
]}

Olaizola, Paula ^{[10
]}

Banales, Jesus M. ^{[10
]}

Gerussi, Alessio ^{[11
,12
]}

Elvevi, Alessandra ^{[11
,12
]}

Busset, Michele Droz Dit ^{[13
]}

Bhoori, Sherrie ^{[14
]}

Mazzaferro, Vincenzo ^{[15
]}

Alpini, Gianfranco ^{[16
,17
,18
]}

Marra, Fabio ^{[19
]}

Invernizzi, Pietro ^{[20
]}

机构：

[1] Univ Florence, Florence, Italy

[2] Humanitas Clin & Res Ctr, Rozzano, Italy

[3] Arqule Inc, Woburn, MA USA

[4] Humanitas Res Inst, Rozzano, MI, Italy

[5] Humanitas Res Hosp, Pathol Unit, Rozzano, MI, Italy

[6] Richard L Roudebush VA Med Ctr, Div Gastroenterol & Hepatol, Dept Med, Indianapolis, IN USA

[7] Indiana Univ, Bloomington, IN 47405 USA

[8] Texas A&m Hlth Sci Ctr, Bryan, TX USA

[9] Fdn Edo & Elvo Tempia, Canc Genom Lab 8, Biella, Italy

[10] Univ Basque Country UPV EHU, Dept Liver & Gastrointestinal Dis, Biodonostia Res Inst, Donostia Univ Hosp,Ciberehd,Ikerbasque, Leioa, Spain

[11] Univ Milano Bicocca, Div Gastroenterol, San Gerardo Hosp, Dept Med & Surg, Monza, Italy

[12] Univ Milano Bicocca, Ctr Autoimmune Liver Dis, San Gerardo Hosp, Dept Med & Surg, Monza, Italy

[13] Ist Nazl Tumori Irccs Fdn, Hpb Surg & Liver Transplantat, Milan, Italy

[14] Ist Nazl Tumori Irccs Fdn, Gastroenterol & Liver Transplant Hepatol, Milan, Italy

[15] Natl Tumor Inst, Milan, Italy

[16] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA

[17] Indiana Univ, Gastroenterol, Med, Bloomington, IN 47405 USA

[18] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA

[19] Univ Florence, Dipartimento Med Sperimentale & Clin, Florence, Italy

[20] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

355

引用

页码：226A / 227A

页数：2

共 50 条

[1] Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma
Raggi, Chiara
Fiaccadori, Karim
Pastore, Mirella
Correnti, Margherita
Piombanti, Benedetta
Forti, Elisa
Navari, Nadia
Abbadessa, Giovanni
Hall, Terence
Destro, Annarita
Di Tommaso, Luca
Roncalli, Massimo
Meng, Fanyin
Glaser, Shannon
Rovida, Elisabetta
Peraldo-Neia, Caterina
Olaizola, Paula
Banales, Jesus M.
Gerussi, Alessio
Elvevi, Alessandra
Busset, Michele Droz Dit
Bhoori, Sherrie
Mazzaferro, Vincenzo
Alpini, Gianfranco
Marra, Fabio
Invernizzi, Pietro
AMERICAN JOURNAL OF PATHOLOGY, 2019, 189 (10): : 2090 - 2101
[2] Fibroblast growth factor receptor (FGFR) inhibitor Treatment of intrahepatic cholangiocarcinoma
Shaib, W. L.
El-Rayes, B. F.
DRUGS OF THE FUTURE, 2017, 42 (11) : 677 - 683
[3] Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion
Kawano, Satoshi
Kawada, Megumi ikemori
Fukushima, Sayo
Arai, Yasuhito
Shibata, Tatsuhiro
Miyano, Saori watanabe
ANTICANCER RESEARCH, 2024, 44 (06) : 2393 - 2406
[4] Tumor vascularity as a predictor of FGFR inhibitor response in FGFR2-fused intrahepatic cholangiocarcinoma.
Meza, Kelly
De Leon, Sergio Villegas
Pant, Shubham
Tang, Tin-Yun
Meric-Bernstam, Funda
Hu, Zishuo Ian
Javle, Milind M.
Lee, Sunyoung S.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[5] Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
Wu, Tianyu
Jiang, Xiaoqing
Zhang, Xin
Wu, Bodeng
Xu, Bin
Liu, Xiaoliu
Zheng, Lei
Wang, Yu
CANCER CONTROL, 2021, 28
[6] Detection of Known and Novel FGFR2 Geneomic Alterations in Intrahepatic Cholangiocarcinoma
Pu, Xiaohong
Fu, Yao
Fan, Xiangshan
Chen, Jun
Sun, Beicheng
LABORATORY INVESTIGATION, 2023, 103 (03) : S1405 - S1407
[7] Antitumor Effect of the Potent FGFR Inhibitor Ponatinib on an FGFR2-Fusion Driven Cholangiocarcinoma Mouse Model
Shaleh, Hassan M.
Wang, Yu
Ding, Xiwei
Allotey, Loretta K.
Mohamed, Essa
Chen, Gang
Moser, Catherine D.
Chaiteerakij, Roongruedee
Gozgit, Joseph
Borad, Mitesh
Roberts, Lewis R.
GASTROENTEROLOGY, 2015, 148 (04) : S1017 - S1017
[8] FGFR2 in-frame indels: A novel targetable alteration in intrahepatic cholangiocarcinoma
Li, Yvonne Y.
Cleary, James M.
Raghavan, Srivatsan
Spurr, Liam F.
Wu, Qibiao
Shi, Lei
Brais, Lauren K.
Loftus, Maureen
Goyal, Lipika
Patel, Anuj K.
Shinagare, Atul B.
Clancy, Thomas E.
Shapiro, Geoffrey
Cerami, Ethan
Sellers, William R.
Hahn, William C.
Meyerson, Matthew
Bardeesy, Nabeel
Cherniack, Andrew D.
Wolpin, Brian M.
CANCER RESEARCH, 2020, 80 (16)
[9] FGFR-2 inhibitor for cholangiocarcinoma
Collingridge, David
LANCET ONCOLOGY, 2022, 23 (10): : E447 - E447
[10] Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Valle, Juan W.
Morizane, Chigusa
Karasic, Thomas B.
Abrams, Thomas A.
Furuse, Junji
Kelley, Robin K.
Cassier, Philippe A.
Kluempen, Heinz-Josef
Chang, Heung-Moon
Chen, Li-Tzong
Tabernero, Josep
Oh, Do-Youn
Mahipal, Amit
Moehler, Markus
Mitchell, Edith P.
Komatsu, Yoshito
Masuda, Kunihiro
Ahn, Daniel
Epstein, Robert S.
Halim, Abdel-Baset
Fu, Yao
Salimi, Tehseen
Wacheck, Volker
He, Yaohua
Liu, Mei
Benhadji, Karim A.
Bridgewater, John A.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (03): : 228 - 239

← 1 2 3 4 5 →